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Abstract
Dengue is widespread throughout the tropics globally in more than hundred coun-
tries and coincides with various climatic factors for co-infection with other flaviviral 
infections of the central nervous system (CNS). Dengue and Japanese encephalitis 
virus co-infection are highly prevalent, with diagnosis dilemma including significant 
mortality and morbidity in Southeast Asia. Both dengue and Japanese encephalitis 
transmissions intensify during the rainy season, during which the vector population 
increases. CNS involvement during dengue and Japanese encephalitis co-infection-
associated acute encephalitis syndrome (AES) is still poorly understood, and therefore, 
there is a desperate need to understand the etiology, therapeutics, clinical manage-
ment, and prevention of these tropically neglected diseases. AES can be differentiated 
from other etiologies of encephalopathy through considering its essential features: sud-
den onset of fever, cerebrospinal fluid (CSF) comprising inflammatory cells, magnetic 
resonance imaging (MRI)-based confirmation, and presence of pathogen or pathogen-
specific antibodies. Complementary and alternative medicine is progressively being 
used globally and can be effective for the overall management of this co-infection.
Keywords: dengue, Japanese encephalitis, co-infection, encephalitis,  
acute encephalitis syndrome (AES), differential diagnosis, treatment, management, 
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1. Introduction
Neglected tropical diseases (NTDs) are the diverse group of communicable 
diseases which exist in tropical and subtropical settings affecting more than one bil-
lion people worldwide [1]. Populations inhabiting places with poor sanitation are in 
close contact with infected vectors, and domestic animals are principally affected. 
Arthropod-borne or arboviruses such as dengue, Zika, and Chikungunya have been 
recently included in the list of NTDs by the World Health Organization [2].
Human infection of flavivirus may cause severe clinical manifestations and can 
be broadly subdivided into two groups as neurological diseases caused by Japanese 
encephalitis virus (JEV), West Nile virus, and Zika virus (ZIKV) and hemorrhagic 
and viscerotropic diseases caused by dengue virus (DENV), ZIKV, and yellow fever 
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virus (YFV) [3]. More than half of the global population is now at the risk of getting 
flavivirus infections where the majority of areas are endemic for more than one flavi-
viruses which results in the phenomenon of co-infection [4]. The worldwide incident 
of dengue has extensively grown in few decades [5]. Majority of the dengue cases 
are asymptomatic, and therefore, it is hard to anticipate the accurate burden of the 
disease. The rise in number of cases from 2.2 million in the year 2010 to 3.34 million 
cases in 2016 suggests the sharp increase in the disease burden. The 2016 year is char-
acterized as the largest outbreak for dengue where 2.38 million cases were reported 
from the region of the Americas where 1.5 million cases were contributed by Brazil 
alone. Currently 3.9 billion in 128 countries people are at risk of DENV infection [6]. 
Unlike dengue, Japanese encephalitis (JE) is confined to Southeast Asia and Western 
Pacific regions. Approximately 68,000 clinical cases of JE are reported annually with 
13,000 to 24,000 deaths. Currently more than 3 billion in 24 countries are at risk of 
JEV infection [7]. The epidemiology of dengue and JE has been depicted in Figure 1.
DENV and JEV belongs to the Flaviviridae family, which consists of more than 
70 viruses, comprising of single-stranded positive-sense RNA genome protected by 
envelope protein [8]. Viruses from this family belong to the genus Flavivirus, which 
are transmitted by mosquitoes or ticks and are characterized as arthropod-borne 
infections. The transmission cycle of Flavivirus involves animals including human 
which are considered to be the dead-end hosts [9]. Hematophagous mosquitoes are 
the transmission vector for these diseases. Aedes albopictus and Aedes aegypti mos-
quitoes are known to transmit the dengue virus, whereas Culex tritaeniorhynchus 
is predominantly involve in the transmission of JEV [10]. These viruses have been 
shown to be transmitted via transplacental route as well [11].
Pathogen-associated acute encephalitis syndrome (PA-AES) may result from 
diverse pathogenic infections including DENV and JEV. PA-AES shows a wide range 
of symptoms including headache, vomiting and severe illness, reduced conscious-
ness, altered sensorium, convulsions, and tremors [12]. Flaviviruses share sub-
stantial sequence similarities to stimulate sero-cross-reactivity which results in the 
antibody-dependent enhancement (ADE) of infection with other flaviviruses [13]. 
Figure 1. 
Dengue and Japanese encephalitis epidemiology. The worldwide epidemiology of dengue and Japanese 
encephalitis has been depicted in this map. More than 100 countries are endemic for dengue where America, 
Western Pacific regions, and Southeast Asia are mostly affected. The Japanese encephalitis is confined to mostly 
in Southeast Asia and Western Pacific regions which include approximately 24 countries. The dengue-affected 
regions are highlighted in red color, JE-affected regions are highlighted in yellow color, and regions where both 
viruses are circulating have been highlighted in orange color.
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Outbreaks of DENV co-infection are predominantly associated with the JEV 
endemic area or areas of JE immunization [14]. Although DENV-induced encepha-
litis is rare, the co-infection may increase the severity of encephalitis. DENV 
infection causes dengue hemorrhagic fever (DHF), whereas JEV infection may 
result in neurological complications [15]. Intermittently, DENV has been reported 
to cause encephalitis, and JEV infection may cause extraneural hemorrhage [16, 17]. 
However, this may not be the case in co-infection with both the flaviviruses. 
Simultaneous detection of both the viruses is not unusual; nevertheless we need to 
be attentive in the diagnosis of the etiology of PA-AES.
2. Molecular mechanism of DENV and JEV co-infection
Co-infection with both viruses may occur in the single-cell types or different 
cells in the infected individuals. Simultaneous infection of target cells or different 
cell types by DENV and JEV defines the phenomenon of co-infection [18]. Both the 
viruses share common cell surface receptors expressed on target cell types such as 
DC-SIGN, mannose receptors, and CLEC5A [19]. On the other hand, virus can be 
internalized in the presence of non-neutralizing antibodies via Fcγ receptor-mediated 
endocytosis [20]. Clathrin-mediated endocytosis has been shown to be involved in the 
internalization of flaviviruses [21]. After internalization, the virus from the endocytic 
vesicles is delivered to the early endosomes [22]. Acidification of the endosomal 
Figure 2. 
DENV and JEV co-infection. The mechanism of co-infection has not been completely understood. 
Co-infection with DENV and JEV may occur in the single-cell types or different cells in the infected individuals. 
Co-infection results in the generation of antibodies against both viruses. However, detection of nucleic acids 
and antigens may confirm the phenomenon of co-infection (A). Upon infection, JEV is internalized by 
receptor-mediated endocytosis. The decrease in pH causes the fusion of viral and endosomal membrane which 
results in the release of viral RNA into the cytosol. The released viral genome is then translated prior to the 
commencement of replication. Virus maturation occurs at the Golgi complex and mature virus is released via 
the egress process. JEV infection in the hyperendemic area may result in false-positive diagnosis due to presence 
of pre-existing sero-cross-reactive antibody (B). Pre-existing sero-cross-reactive antibodies may bind to the 
viral particles upon infection which results in antibody-dependent enhancement of infection (C).
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compartments causes trimerization of the envelope protein that results in the fusion 
of endosomes to the viral membrane and release of nucleocapsid in the cytosol [23].
The released viral genome is then translated prior to the commencement of 
replication [24]. The backbone of flaviviral genome is invariable which are of ~10 kb 
that codes for three structural capsid (C), premembrane (prM), and envelope (E) 
and seven nonstructural proteins NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5. 
The viral genome encodes for 3400 amino acid long polyprotein which is arranged 
in the lumen endoplasmic reticulum where the replication takes place by the RNA-
dependent RNA polymerase [25]. Replicated copies of the genome interact with viral 
proteins to form nucleocapsid. Immature virions enter into the secretary pathway 
where furin-mediated cleavage of prM results in the maturation of virus [26]. 
Mature virus is then released from the infected cells via the egress process [27]. The 
conventional mechanism of pathogenesis and viral replication may not be followed in 
case of co-infection and may involve distinct process. In order to effectively control 
and treat the co-infection of DENV and JEV, we need to first understand the immu-
nopathogenesis of dual infection in various cell and animal models. The probable 
phenomenon of DENV and JEV co-infection has been demonstrated in Figure 2.
3. Diagnostic schemes for dengue and Japanese encephalitis co-infection
JEV is the most documented causative agent of acute encephalitis syndrome (AES) 
[28]. DENV has also been considered among the top three etiological agents causing 
Figure 3. 
Laboratory diagnostic algorithms during DENV and JEV co-infection. Suspected cases of DENV and 
JEV co-infection can be decided by the above laboratory diagnostic algorithms of co-infection. Detection of IgG 
antibodies against both viruses may be considered as the previous exposure of the viruses, whereas detection 
of IgM or NS1 antigen suggests the recent or current infectious conditions. However, this should be further 
validated based on the nucleic acid-based tests such as RT-PCR and isolation of virus which may define the 
co-infectious condition in addition to the clinical correlation. “Y” indicates positive, “N” indicates negative, and 
“?” indicates inconclusive test report.
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AES [29]. Broad spectrum of clinical features in the endemic areas of both viruses 
may dilute the encephalitis-like clinical presentation. Therefore, laboratory based 
diagnosis and discrimination of pathogenesis is crucial to understand. Detection of 
IgG antibodies against both viruses may be considered as the previous exposure of the 
viruses, whereas detection of IgM suggests the recent or current infectious condi-
tions. However, this should be further validated based on the nucleic acid-based tests 
where detection of DENV and JEV nucleic acids defines the co-infectious condition.
Nucleic acid-based detection by RT-PCR for other probable arboviral infections 
such as Zika and Chikungunya can also be included which may overlap with the 
clinical manifestations of dengue or JE [30]. Although the clinical manifestations 
presented in the individual cases of DENV and JEV infections are distinct, the co-
infection might be a complex situation to diagnose. Co-detection of serum anti-
bodies against both viruses may not be the evidence of co-infection. Surveillance 
programs conducted in the hyperendemic areas of flaviviruses have reported at 
least 9% of co-infections cases [31]. Moreover, the MRI findings of DENV-infected 
patients may show the characteristic features of encephalitis as in case of JEV 
where the basal ganglia, thalamus, and midbrain are predominantly affected 
[32]. Considering the sero-cross-reactivity among flaviviruses, the dependence 
of serum-based diagnosis may give false-positive results. However, simultaneous 
detection of nucleic acid or viral-specific antigens in blood or CSF samples may 
define the incident of co-infection. The laboratory diagnostic algorithms during 
DENV and JEV co-infection have been depicted in Figure 3.
4. Treatments regimes for dengue and Japanese encephalitis co-infection
Viral infections have always been a global threat to mankind due to scarcity of 
effective antiviral drugs. Flaviviral infections are not the exception since there is no 
specific treatment available for both DENV and JEV [33]. The overall treatment relies 
on the symptomatic relief of the patients. Due to the complex and unclear pathogen-
esis of dual infection, the potential candidate drugs may not effective. Therefore, we 
need to look for the complementary and alternative medicine (CAM) in alliance with 
conventional medicines as the choice of treatment during co-infection.
In case of DENV infection, various forms of CAM have been used such as 
Carica papaya leaf extracts is the most accepted one. Platelet-activating factor 
receptor (PTAFR) gene has been shown to be upregulated upon consumption of 
Carica papaya leaf extracts or its juices [34]. In case of sever dengue infection, 
maintenance of body fluids volume of the patients is critical [35]. However, this 
may or may not be effective in case of co-infections. Recently, andrographolide has 
been shown to exhibit anti-DENV activity [36]. Eupatorium perfoliatum which is a 
homeopathic medicine has been shown to exhibit anti-DENV activity [37]. Luteolin 
has been shown to be effective during JEV infection which also exhibits direct 
virucidal activity [38]. Similarly, belladonna has been shown to be effective in chick 
embryos infected with JEV [39]. Several of the CAM-based therapies have been 
shown to be effective in case of JEV infection, but these have to be validated in case 
of co-infection.
5.  Preventive strategies for dengue and Japanese encephalitis 
co-infection
To prevent the worldwide burden of DENV infection, the WHO has recently 
approved a tetravalent vaccine, Dengvaxia (CYD-TDV) in 20 countries. This has 
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been designed by using the yellow fever vaccine backbone expressing the prM and 
envelope protein of DENV 1–4 serotypes [40]. In case of JEV, a live attenuated 
vaccine based on SA 14–14-2 has been used in China, India, Sri Lanka, Republic 
of Korea, and Thailand. Due to higher sero-cross-reactivity, the one vaccine may 
induce the other infection due to the antibody-dependent enhancement [41]. 
Therefore, to design an effective vaccine for co-infection, there is a need to under-
stand the mechanism and probability of sero-cross-reactivity among the viruses. 
Apart from the vaccination, the personal preventive measures are always the 
paramount to prevent any vector-borne infections [42]. To prevent the mosquito 
biting, several protective measures include mosquito repellents, mosquito nets, and 
use of full sleeves cloths [43].
6. Conclusions
Genomic and proteomic sequence similarity among the flaviviruses causes 
the sero-cross-reactivity that leads to the phenomenon of antibody-dependent 
enhancement of infections. Incidence of DENV and JEV co-infection in the hyper-
endemic areas may be frequently reported. The diagnosis of co-infection should 
not rely on the presence of serum antibodies. However, simultaneous detection of 
nucleic acids or antigens may define the condition of co-infection. Clinical features 
may overlap in the patients infected with both viruses, and therefore we need to 
precisely distinguish the patients’ clinical reports. Development of effective antivi-
rals targeting both the viruses is the most imperative therapeutic strategy.
7. Future perspectives
Due to the similarity in the structural domains of the viral proteins, molecules 
may be designed to inhibit the action of viral proteins or enzymes. Similarly, 
vaccines may be designed to target the population living in the hyperendemic areas 
of flaviviruses. Peptide-based vaccines may be designed by using various immu-
noinformatics approaches by considering the consensus peptide sequences among 
the viruses. Apart from the vaccination, personal preventive measures are always 
recommended the best practice to reduce the chances of infections.
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